Bristol-Myers Squibb and others colluded to maintain virtual monopoly for cancer drug, Mayo Clinic says in suit

It was to Bristol Myers Squibb's and Celgene's benefit to give generic drug makers a cut of the revenue from the multibillion-dollar cancer drug, the lawsuit says.